Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 13, 2013 - Issue 2
Submit an article Journal homepage
130
Views
4
CrossRef citations to date
0
Altmetric
Review

Review of the economic evaluations of hormonal therapy for patients with locally advanced prostate cancer

Hind T Hatoum Hind T Hatoum & Company, 155 N Harbor Drive, 1912, Chicago, IL 60601, USA. [email protected]
,
E David Crawford University of Colorado, Denver, Mail Stop #F710, PO Box 6510, Aurora, CO 80045, USA
,
Sandy Kildegaard Nielsen European Market Access Ferring International Center SA, Chemin de la Vergognausaz 50, CH-1162 St. Prex, Switzerland
,
Swu-Jane Lin Adjunct Faculty, Department of Pharmacy Administration, College of Pharmacy, University of Illinois at Chicago, 833 South Wood St., Chicago, IL 60612, USA
&
Dennis C Marshall Medical Affairs, Ferring Pharmaceuticals, Inc. 4 Gatehall Drive, Parsippany, NJ 07054, USA
Pages 251-259 | Published online: 09 Jan 2014

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Athanasios Dellis & Athanasios Papatsoris. (2016) Cost–effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer. Expert Review of Pharmacoeconomics & Outcomes Research 16:1, pages 5-10.
Read now
Athanasios Dellis & Athanasios G Papatsoris. (2014) The economics of abiraterone acetate for castration-resistant prostate cancer. Expert Review of Pharmacoeconomics & Outcomes Research 14:2, pages 175-179.
Read now

Articles from other publishers (2)

Richard De Abreu Lourenco & Scott Williams. (2019) Health Technology Assessment and Health Care Utilisation in the Management of Early Prostate Cancer. European Urology Focus 5:2, pages 134-136.
Crossref
Chi Nguyen, David R. Lairson, Michael D. SwartzXianglin L. Du. (2019) Cost-Effectiveness of Adding Androgen Deprivation Therapy to Radiation Therapy for Men with Advanced Prostate Cancer from a U.S. Payer’s Perspective. Journal of Managed Care & Specialty Pharmacy 25:2, pages 225-234.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.